Drug intelligence / Profile preview

APS08

Development stage: Preclinical
Lead developer: Applied Pharmaceutical Science
Modality: Small Molecules

Overview

APS08 is a small molecule pan-KRAS inhibitor developed by Applied Pharmaceutical Science. It is designed to target multiple oncogenic KRAS mutations, specifically G12C, G12D, G12V, and G13D. These mutations are prevalent drivers in various malignancies, including pancreatic cancer, colorectal cancer, and non-small cell lung cancer (NSCLC). Unlike mutation-specific inhibitors, APS08 aims to provide a broader therapeutic reach by inhibiting several common KRAS variants simultaneously. It is currently in the lead discovery stage of development for the treatment of multiple solid tumors.

Targets

KRASG12V (KRAS G12V)KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)Kirsten rat sarcoma viral oncogene homolog mutated proteinKRASG12D (Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutant)

Beyond the preview

Go deeper on APS08.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APS08.

Explore the full profile